Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATR-PAT
2024-511868-83-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in antisynthetase syndrome (ASSD) comparing Cyclophosphamide → Azathioprine with Tacrolimus (2 arms). Primary endpoint: Progression-free survival for ASS-related ILD. Planned start Feb 2021; status: authorised.
02
Drugs
tacrolimusazathioprinecyclophosphamide
03
Conditions
antisynthetase syndrome (ASSD)
Beyond the preview
Go deeper on 2024-511868-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511868-83-00.